Carla Coffin

cscoffin@ucalgary.ca


In-person interactions impact on HCV, HIV, and Syphilis Rates in At Risk Populations

Pam Ford

Targeting the hepatitis B virus covalently closed circular DNA genome using a G-quadruplex specific single domain antibody

Simmone D'Souza

HDV is uncommon in Toronto but can have an aggressive clinical course: interim analysis

David Wong

Biologiste Médical

Ronald Simeon

Impact of COVID-19 pandemic–related measures on testing for hepatitis B in British Columbia, Canada: an interrupted time series analysis

Richard Morrow

Clinical Science Advances in Hepatitis B (HDV, HCV, HIV Co-infections): A Comprehensive Review

Moses Donkor

Epidemiology and Public Health Implications of Hepatitis B, HDV, HCV, and HIV Co-infections

Desmond Osei

EPIDEMIOLOGY, TREATMENT PATTERN, AND SURVIVAL IN CANADIAN PATIENTS WITH CHRONIC HEPATITIS B RELATED HEPATOCELLULAR CARCINOMA

Yashasavi Sachar

HCC RISK STRATIFICATION USING RANDOM SURVIVAL FORREST MACHINE LEARNING MODEL OUTPERFORMS TRADITIONAL ANALOG SCORING

Yashasavi Sachar

Hepatitis B core antibody is associated with liver fibrosis in people with HIV independently of MASLD

Dong Hyun (Danny) Kim

Initial HBV-Hepatocyte Genomic Integrations, Their Formation and Potential Role in Oncogenesis

Thomas Michalak

Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Alexa Thompson

Compassionate use of REP 2139-Mg in HBV / HDV / HIV co-infection: a first Canadian experience

Sébastien Poulin

Functional cure of chronic HBV infection

David Wong

Using discrete field documentation in Epic EMR for clinical research of hepatitis B

David Wong

A DNA knot not like any other - exploring the specificity of HBV’s promoter G4-quadruplex

Archee Panwar

Intravital Imaging of the Liver Microenvironment in The Woodchuck Model of Hepatitis B Virus Infection

Layla Al-Yasiri

Chronic HBV infection in Toronto, Canada: Tale of two clinics

David Wong

Demographic Characteristics of Hepatitis B-Infected Sub-Saharan African Immigrants in Canada.

Nana Frimpong

Determining a Hepatitis Delta virus (HDV) peptidomimetic therapeutic to target Hepatitis B virus (HBV)

Justine Beghin

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Epidemiology and Natural History of Chronic Hepatitis B in the Canadian Province of Alberta from 2012 to 2021: A Population-based Study

Golasa Samadi Kochaksaraei

Epidemiology, Linkage to Care and Natural History of Women of Childbearing Age with Chronic Hepatitis B: A Population-based Study

Golasa Samadi Kochaksaraei

Defining a Hepatitis D Virus Antibody Testing Algorithm for Accurate Screening

Carla Osiowy

IL-2 Produced by HBV-specific T cells as a Biomarker of Viral Control and Predictor of Response to PD-1 Therapy Across Clinical Phases of Chronic Hepa

Loghman Salimzadeh

Next Generation Sequence (NGS) Analysis for Hepatitis B Virus (HBV) Outbreak Transmission Analysis in Manitoba

Carla Osiowy

Prevalence and Clinical Characteristics of Hepatitis Delta Virus (HDV) Infected Individuals in British Columbia

Valeriya Zaborska

PSMA-Targeted Radionuclide Therapy of Hepatocellular Carcinoma in a Woodchuck Model

Hoda Poorbagher

G4Q-binding ligands: a starting point for potential cure therapies for chronic hepatitis B infections

Jessica Skoreyko

Cracking the HBV Code: Unravelling the specificity of SP1 with G-Quadruplex for next- generation cccDNA inhibitors

Kuldeep Kaur

Effect of HBV treatment on all-cause and liver-related death among individuals with HBV and cirrhosis in British Columbia: a population-based cohort

Jean Makuza

Hepatitis B Virus Genotype (GT) Does Not Influence Virological and Enzymatic Measures Over Time

Curtis Cooper

Prevalence of Hepatitis B Among Adults Receiving Immunosuppressive Therapy At a Tertiary Care Center in Saudi Arabia

Abdulrhman Alamr

Hepatocellular carcinoma (HCC) in patients followed in two clinics in Toronto

David Wong

Experience of a Chinese Hepatitis B Peer Support Group (PSG): Successes and Challenges

Colina Yim

Small molecules approach in HBV treatment:preventing transcription in the pre-core promoter by blocking a G-quadruplex with mithramycin and daunorubin

Kira Sviderskaia

Kinetics of Quantitative HBsAg Decline in Chronic Hepatitis B Patients Receiving Nucleos(t)ide Antiviral Therapy

Frank Hyun

Opening the X-files: Exploring HBx protein’s role in transcriptional enhancement

Emma Kasinyabo

Establishment of HBx responsive quantitative cell culture reporter system for monitoring HBV infection

Muhammad Atif Zahoor

Unravelling an important DNA knot – analysis of HBV’s promoter G4-quadruplex

Mohaddeseh Pakzamir

Production of recombinant woodchuck surface antigen and antibodies for use in ELISAs, ELISpots, and western blots

Michelle Tang

Anchoring Hepatitis B: Investigation of HBV promoter binding with zinc finger Specificity protein 1 and G4-quadruplex binding drugs

Samantha Polege

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Guanine quadruplexes and host transcription factor interactions: Targeting viral cccDNA to treat chronic HBV.

Nikolas Shapka

Alexa Thompson

Under Review

Profile Summary

Submission ID PROLEC0JKP7
Name Alexa Thompson
Call Progress toward Hepatitis B Elimination Meeting in Canada - Abstract Submission
Email Address lathomps@ualberta.ca
Title PhD Candidate
Organization University of Alberta

Session

Title Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022
Description

Title: Investigating HDV screening rates and associated demographic characteristics among first-time HBV positive patients in Alberta from 2018-2022

Background: Hepatitis D virus (HDV) occurs exclusively in Hepatitis B virus (HBV) carriers and increases risk of severe liver disease. However, the proportion of HBV carriers screened for HDV in Alberta remains unclear.

Purpose: We aimed to identify the proportion and demographic characteristics of first-time HBV carriers in Alberta screened for HDV.

Methods: HBV data was extracted from public health laboratory records between January 01, 2018-December 31, 2022 and linked to HDV testing data within 6 months of HBV diagnosis using patient PHN. Demographic characteristics were compared between individuals screened and not screened for HDV using Chi-Square tests. Geographic region and income quintile were analyzed using Alberta 2016 census estimates.

Results: From 3643 unique first-time HBV carriers, 264 (7.25%) were screened for HDV. Individuals aged 21-40 (48.5%, p<0.001), males (64.6%, p<0.001), and those living in metropolitan regions (86.6%, p=0.020) were most likely to receive HDV screening. HBV/HCV coinfected individuals were not more likely to receive screening compared to those with HBV monoinfection (p=0.215). All other demographics were statistically insignificant.

Conclusions: Overall, HDV screening was low in HBV carriers. A higher number of females were positive for HBV compared to males, yet the proportion screened for HDV was lower. More efforts should focus on HDV screening among HBV carriers who are older, females, those residing in rural regions, and those with HCV coinfection.

Track Hepatitis B (including HDV, HCV, HIV Co-infections) - Epidemiology/Public Health
Formats
Audiences

Co-Presenters

Name Carmen Charlton
Organization Canadian Blood Services
State/Province
City
Email carmen.charlton@blood.ca
Website N/A
Speaker Role
Name Joelle Kasongo
Organization University of Alberta
State/Province
City
Email jkasongo@ualberta.ca
Website N/A
Speaker Role
Name Rachel Ha
Organization Alberta Precision Laboratories (ProvLab)
State/Province
City
Email rachel.ha@albertaprecisionlabs.ca
Website N/A
Speaker Role

Submit Review



Is this abstract accepted for a poster presentation? *
Is this abstract accepted for a trainee travel grant?